Α,β-methylene-atp-induced Inhibition of Acetylcholine Release on the Stellate Ganglion: Contribution of Nitric Oxide Pyridoxalphosphate-6-azophenyl-2',4'-disulphonic Acid (ppads); the P2x 1 , P2x 3 and P2x 2/3 Re- Ceptors Antagonist, 2'-(or-3')-o-trinitrophenyl-atp (tnp-atp); the Neuronal Nitric Oxi

In this study, we investigated the possible involvement of nitric oxide pathways in the presynaptic inhibition of acetylcholine release induced by ATP analogs in dogs. We performed the study using HPLC with electrochemical detection and the nitric oxide detection-HPLC system. The amount of acetylcholine released in response to preganglionic stimulation at 5 Hz for 10 min was reduced in a concentration-dependent manner after exposure to 10 −7-10 −4 M α,β-methylene-ATP (α,β-meATP), but not by the P2Y receptor agonist, 2-methyl-thio-ATP (2MeSATP) or the P2X 1 receptor agonist, β,γ-methylene-ATP (β,γ-meATP), at the same concentrations. The inhibition of acetylcho-line release induced by α,β-meATP was antagonized by: the nonselective P2 receptor antagonist, − NO x , and this increase was antagonized by TNP-ATP and 3-bromo-7-nitroindazole. These results show that P2X receptor activation inhibits stellate ganglionic transmission by reducing acetylcholine release from presynaptic nerve terminals and that this inhibition seems to involve, at least in part, the activation of endogenous NO production and cGMP pathways .


Introduction
A role for ATP in autonomic ganglia was first reported in 1948 when Feldberg and Hebb demonstrated that the intra-arterial injection of ATP in cats excited neurons in the superior cervical ganglia [1].Later, work from de Groat's laboratory showed that purines inhibited synaptic transmission through adenosine receptors in cat vesical parasympathetic ganglia and rat superior cervical ganglia, but that high concentrations of ATP depolarized and excited the postganglionic neurons [2].
The rat superior cervical ganglion contains P2X receptors that are activated by ATP or a selective P2X receptor agonist, α,β-methylene-ATP (α,β-meATP), which depolarizes these neurons [3].A reduction of the amount of acetylcholine released from preganglionic nerve terminals by ATP may result from a decrease in Ca 2+ influx, due mainly to a depolarization of the preganglionic nerve terminals [4].P2X receptors are important for synaptic transmission in enteric ganglia, although their roles in sympathetic and parasympathetic ganglia are less clear [5].
There is increasing evidence that ATP plays a role in neurotransmission in mammalian autonomic ganglia [2] [6].The pharmacological effects of ATP in neurons have been studied in many ganglia, including the dorsal root ganglion [7] [8], the nodose ganglion [9], the superior cervical ganglion [10] [11], and the celiac ganglion [12] [13].In the guinea pig, α,β-meATP is an effective agonist of superior cervical ganglia [11] [14] and celiac ganglion neurons [9].In contrast, α,β-meATP evoked only small and slowly desensitizing responses in a subpopulation of neurons from the rat superior cervical ganglion [9] [15].In a study of rat and mouse celiac ganglion neurons, no response to α,β-meATP was detected [16].Based on these data, Burnstock has shown that there is a species difference between rat and guinea pig [2].While the responses to purines in the autonomic ganglionic transmission of many species have been investigated, there are few reports describing the actions of purines on sympathetic ganglionic transmission in canines.
Studies describing the effects of ATP analogs on the direct and chemical determination of classical neurotransmitter release in the sympathetic ganglia are insufficient to characterize the specific biochemical/receptor mechanisms of ganglionic transmission in canines.According to past research [17]- [20], the isolated canine stellate ganglion serves as a convenient and readily accessible model that can contribute to our understanding of cholinergic transmission.Thus, in the current study, we investigated the presynaptic effects of ATP analogs on ganglionic transmission by directly measuring acetylcholine release caused by preganglionic electrical stimulation in order to determine the possible biochemical/receptor mechanisms involved.
Our interest in exploring the specific role of nitric oxide (NO) in ganglionic transmission stems from the fact that it has been shown to play an important role in the control of synaptic function in both the peripheral and central nervous systems [21].NO is synthesized in neurons by the activation of NO synthase (NOS) in a Ca 2+calmodulin-dependent manner, in the presence of l-arginine as substrate, tetrahydrobiopterin, and nicotinamide adenine dinucleotide phosphate (NADPH) [22].NOS is found in the majority of preganglionic cholinergic neurons of the sympathetic nervous system in rats [23] [24], guinea pigs [25], cats [26] [27], mice, and monkeys [26].The histochemical results have shown that ATP and NO coexist in a subpopulation of ganglionic neurons in the ileum, proximal colon, and anococcygeus muscle of rat [28].Previously, we demonstrated that the neuropeptide endothelin inhibited sympathetic ganglionic transmission at presynaptic sites via the endothelin-B receptor by reducing acetylcholine release through the stimulation of NO production and the cGMP pathways [20].
The aim of this study was to investigate the effects of purinergic signaling on the presynaptic release of acetylcholine and its effects on canine sympathetic ganglionic transmission.

Animals
Adult mixed-breed dogs of both sexes, provided by the Fukuoka City Animal Control Center, were housed at the Fukuoka University Animal Center for about one week while they underwent a general medical examination.Each dog was housed in an individual cage in a room in which the temperature was maintained at 22˚C, humidity at 50% -60%, and illumination was alternated on a 12-h light/dark cycle.All animals had free access to water and were fed 300 g standard solid laboratory diet (ED-1, Sanwa Chemicals Inc., Tokyo, Japan) per dog per day.Only animals in good physical health were used in the experiments.Experimental protocols were approved by the Animal Care Committee of Fukuoka University and were in accordance with the principles outlined in the NIH Guide for the Care and Use of Laboratory Animals.

In Vitro Experiments on the Ganglia
All dogs (6 -12 kg) were anesthetized with pentobarbital sodium (30 mg/kg, i.v.).Each dog's trachea was cannulated, and artificial ventilation was maintained by a Harvard animal respirator (model 613, Millis, MA).Both stellate ganglia were removed-together with about 3 cm of the preganglionic sympathetic nerve-for the nerve stimulation experiments.
To perform the acetylcholine assays, we placed the ganglia tissue specimens in a dish containing Locke's solution in the presence of physostigmine (10 −6 M) at room temperature; they were then gassed with a mixture of 95% O 2 and 5% CO 2 , and the tissue sheath around the ganglia was carefully removed.The experimental procedures were principally performed according to the methods described by Ohjimi et al. [17].The composition of the Locke's solution was (in mM): NaCl, 136; KCl, 5.6; CaCl 2 , 2.2; MgCl 2 , 1.2; NaH 2 PO 4 , 1.2; NaHCO 3 , 20.0; and glucose, 11.0.
Individual ganglion cells were transferred to micro-test tubes containing 0.7 ml of fresh medium (Locke's solution containing physostigmine, 10 −6 M) at 37˚C, gassed with a mixture of 95% O 2 and 5% CO 2 , and equilibrated for 60 min.The preganglionic nerve was laid across a bipolar platinum electrode suspended just above the surface of the solution and stimulated by 60-V square-wave pulses of 1-msec duration at a frequency of 5 Hz for 10 min each; we used an electric stimulator (SEN-3201, Nihon Kohden) that delivered pulses via an isolation transformer (SS-2015m, Nihon Kohden).The interval between each successive preganglionic stimulation was 10 min.
To measure NO, both sides of the stellate ganglia (without preganglionic nerves) were prepared under the same experimental conditions as those described above.The ganglion was put into a micro-test tube containing 0.5 ml Locke's solution, without physostigmine, at 37˚C and then was gassed with a mixture of 95% O 2 and 5% CO 2 .At the end of the experiment, the ganglion without its nerve trunk was weighed after the removal of any excess moisture by pressing the ganglion between filter paper.
Acetylcholine was measured by HPLC with electrochemical detection, as described by Eva et al. [29] and Potter et al. [30].A standard mixture of acetylcholine, choline and isopropylhomocholine chloride, each at concentrations of 2 × 10 −6 M was prepared daily from a stock solution of 2 × 10 −3 M stored at 4˚C.Isopropylhomocholine chloride, 15 µl of 2 × 10 −5 M, an internal standard, was added into 300 µl of sample solution and filtered through a 0.22 µm membrane filter (UFC30GVOO, Millipore, Tokyo, Japan).Aliquots of the standard and the filtered samples, 5 µl and 10 µl, respectively, were injected into the HPLC system.The temperature of the enzyme column was maintained at about 33˚C by a column heater (U-620, Sugai, and Tokyo, Japan).The mobile phase consisted of 0.1 M disodium hydrogen phosphate, buffered to pH 8.0 with phosphoric acid, containing 0.6 mM tetramethylammonium (TMA) and 1.2 mM sodium 1-decanesulfonate.The buffer was prepared first and filtered through a 0.45 µm membrane filter (Tokyo Roshi, Tokyo, Japan).TMA and sodium 1-decanesulfonate were added, and the solution was degassed by bubbling helium gas at a flow rate of 100 ml/min for 30 min.The pumping rate of the mobile phase was 1.0 ml/min.

Acetylcholine Release
In the experiments performed on the isolated ganglia, the acetylcholine released by untreated ganglia was collected during two 10-min periods by changing the incubation medium.A third aliquot of fresh incubation medium was introduced containing either the agonist (α,β-meATP, 2MeSATP, or β,γ-meATP), as described previously [17], or the antagonist (PPADS, TNP-ATP, 3-bromo-7-nitroindazole, ODQ, or carboxy-PTIO).Fresh medium containing the corresponding agents at the same concentration was introduced after the preincubation to remove the resting amount of acetylcholine released during the preincubation periods.Five to six samples were taken in the acetylcholine assay experiment.
The effects of these drugs on acetylcholine release were evaluated by measuring the acetylcholine released into a 0.7-ml incubation medium during the 10-min period of preganglionic stimulation.Acetylcholine was measured in a 10-μl aliquot of the sample solution by HPLC; the total acetylcholine released into 0.7 ml was calculated, and these values were expressed as a percentage of the initial acetylcholine output elicited by the first preganglionic stimulation.

NO Levels
Isolated ganglia with their preganglionic trunk removed were incubated in tubes containing 0.5 ml Locke's solution and oxygenated with 95% O 2 and 5% CO 2 at 37˚C in a water bath.The output of NO was collected over 30-min periods, separated by 20-min intervals.The first three samples collected were from untreated ganglia and provided a baseline; thereafter, drugs were added and the fourth, fifth, and sixth experimental samples were collected.The left ganglia were used as controls, and the right ganglia were treated with antagonists.Fresh medium containing the same antagonists at the same concentration was used to replace samples removed for NO measurement.Tissues were exposed to agonists (α,β-meATP) for 30 min, and antagonists (TNP-ATP or 3-bromo-7-nitroindazole) for 20 min as described previously [20].
Aliquots of the samples incubated with the drugs were immediately frozen in chilled acetone with dry ice; they were stored below −40˚C until they were used in the assays.The NO metabolite content of the 0.5-ml samples from the 30-min incubations with ganglia were calculated from the values measured in 20-μl aliquots using a NO detector-HPLC system (ENO-20, Eicom, Kyoto, Japan).The values were expressed as a percentage of the NO metabolite output of untreated ganglia during a 30-min incubation.
To measure 2 NO − and 3 NO − in the incubation medium, they were separated using a reverse-phase separa- tion column packed with polystyrene polymer (NO-PAK, 4.6 × 50 mm, Eicom), and 3 NO − was reduced to 2 NO − using a reduction column packed with copper-plated cadmium filings (NO-RED, Eicom).Samples con- taining 2 NO − were mixed with Griess reagent in a reaction coil to form a purple azo dye.The separation and reduction columns and the reaction coil were placed in a column oven at 35˚C.The dye produced was measured at an absorbance of 540 nm using a flow-through spectrophotometer (NOD-10, Eicom).The mobile phase (Eicom) consisted of 10% methanol in 0.15 M NaCl-NH 4 Cl and 0.5 g/l of EDTA-4Na, and it was pumped at a rate of 0.33 ml/min.The Griess reagent (Eicom) was 1.25% HCl containing 5 g/l sulfanilamide with 0.25 g/l Nnaphthyle-thylenediamine and was delivered at a rate of 0.1 ml/min.The background levels of

Statistical Analysis
All values represent mean ± standard error of mean.The differences between more than two mean values of the dose-response effects in the same ganglia were evaluated using Dunnett's test.Comparisons between left control ganglia and right experimental ganglia from the same animal were made using analyses of variance (ANOVA), followed by the Bonferroni t test.Differences were considered significant at p values < 0.05.

Effects of ATP Agonists on Acetylcholine Release
Acetylcholine release in response to preganglionic nerve stimulation is frequency-dependent, increasing to 50% of the maximum at 5 Hz and reaching a maximum at 20 Hz [17].Based on this, we stimulated the preganglionic nerve at a frequency of 5 Hz in these experiments.As shown in Figure 1, the output of acetylcholine induced by preganglionic stimulation in each 10-min period was reduced in a dose-dependent manner in the presence of α,β-meATP at concentrations of 10 −6 to 10 −4 M, with the output reduced to 57.4% of control at the maximum concentrations of 10 −4 M. In contrast, acetylcholine release was not inhibited in the presence of the same concentrations of 2MeSATP or β,γ-meATP.In fact, the increased acetylcholine release induced by preganglionic stimulation was significantly augmented, rather than inhibited by β,γ-meATP at concentrations of 10 −5 and 10 −4 M. When these purine analogs were washed out, the level of acetylcholine output induced by preganglionic stimulation returned to near control levels (Figure 1).

Effects of the Nonselective P2 Receptor Antagonist, PPADS, and the P2X 1 and P2X 3 Receptor Antagonist, TNP-ATP, on the α,β-meATP-Induced Reduction in Acetylcholine Release
As shown in Figure 2 and Figure 3, the α,β-meATP-induced inhibition of acetylcholine release during preganglionic stellate stimulation was antagonized by incubation with 10 −5 M PPADS or TNP-ATP.Incubation with PPADS or TNP-ATP alone in the absence of α,β-meATP did not affect acetylcholine release significantly (Figure 2 and Figure 3).

Reduction of Acetylcholine Release
As shown in Figure 4, the α,β-meATP-induced inhibition of acetylcholine release during preganglionic stellate stimulation was antagonized by incubation with 10 −5 M 3-bromo-7-nitroindazole.The application of 3-bromo-7nitroindazole alone in the absence of α,β-meATP tended to increase acetylcholine release, though not significantly (Figure 4).In a previous canine study [20], incubation with the same concentration of 3-bromo-7-nitroindazole did not significantly affect acetylcholine output elicited by preganglionic stimulation conducted in the same experimental manner.

Effects of Soluble Guanylyl Cyclase Inhibitor, ODQ, on α,β-meATP-Induced Reduction of Acetylcholine Release
As shown in Figure 5, the reduction of acetylcholine output induced by α,β-meATP at concentrations of 10 −7 -10 −4  M was antagonized by incubation with the soluble guanylyl cyclase inhibitor, ODQ, at 10 −5 M. ODQ alone, at the same concentration did not affect acetylcholine release elicited by preganglionic stimulation (Figure 5).Similarly, Yamada et al. [20] had found that ODQ, even at the relatively high concentration of 10 −4 M, did not influence the acetylcholine output elicited by preganglionic stimulation of canine stellate ganglion.

Effects of the NO Scavenger Carboxy-PTIO on α,β-meATP-Induced Reduction of Acetylcholine Release
Carboxy-PTIO is a stable compound and a scavenger of NO radicals that is widely used to remove endogenous NO [33].As shown in Figure 6, the α,β-meATP-induced inhibition of acetylcholine release during preganglionic stellate stimulation was antagonized by incubation with 10 −5 M carboxy-PTIO.Carboxy-PTIO, alone, at the same concentration, did not affect the acetylcholine release elicited by preganglionic stimulation (Figure 6).ATP-stimulated NO production in carotid body efferent glossopharyngeal neurons is inhibited by carboxy-PTIO at a concentration of 10 −4 M [34].As shown in Figure 7 and Figure 8, the α,β-meATP-induced increase in NO x − levels was antagonized by the nNOS inhibitor 3-bromo-7-nitroindazole at 10 −5 M and by the P2X 1 , P2X 3 , and P2X 2/3 antagonist TNP-ATP at 10 −7 M.These agents alone, at the same concentrations did not affect the basal NO x − levels in the absence of α,β-meATP.As we reported in an earlier study [20], endothelin-induced NO production by canine stellate ganglia was completely antagonized by 3-bromo-7-nitroindazole at the same concentration.

Discussion
In this study, we investigated the contribution of the specific ATP receptor subtype and the NO system to the presynaptic inhibition of canine stellate ganglionic nerve transmission induced by ATP agonists.Previous experiments using acetylcholine assays demonstrated that there were no changes in the release of acetylcholine elicited by eight successive preganglionic stimulations at 10-min intervals [17] [18].Under the same experimental conditions, the output of acetylcholine elicited by preganglionic stimulation was modulated by exposure of the isolated stellate ganglia to ATP analogs (α,β-meATP, β,γ-meATP and 2MeSATP) at concentrations between 10 −7 and 10 −4 M.
Abbracchio and Burnstock [35] described "P2X-ˮ and "P2Y-purinoceptorsˮ with distinct pharmacological profiles and tissue distributions.The P2X-receptor was most potently activated by stable analogs of ATP, such as α,β-meATP and β,γ-meATP, whereas for the P2Y receptor, 2MeSATP was the most potent agonist and   α,β-meATP and β,γ-meATP were weak or inactive as agonists.In the experiments described here, preincubation with α,β-meATP reduced the acetylcholine release elicited by preganglionic stimulation in a concentration-dependent manner, whereas the same concentrations of β,γ-meATP augmented acetylcholine release.The discrepancy between these responses to P2X agonists remains to be explained.
In our experiments, the reduction in acetylcholine release elicited by α,β-meATP was completely antagonized by pretreatment with the nonselective P2 receptor antagonist PPADS and by the P2X 1 , P2X 3 and P2X 2/3 antagonist, TNP-ATP.In contrast, in primary cultures of rat superior cervical ganglion neurons, a P2Y agonist, 2MeSATP, and a selective P2Y 1 agonist, MRS2365, significantly enhance the stimulation-induced [ 3 H]-nore-pinephrine overflow from ganglion neurons treated with pertussis toxin, and this effect was abolished by the P2Y 1 antagonist, MRS2179 [36].
In our experiment, 2MeSATP tended to enhance the preganglionic stimulation-evoked acetylcholine release, although the differences were not significant.Although 2MeSATP has been widely regarded as a selective P2Y receptor agonist, it also acts as a potent agonist of P2X receptors [6].Therefore, we have assumed that the nonsignificant, small increase in acetylcholine output induced by preganglionic stimulation in the presence of 2MeSATP is likely to represent the average effect of 2MeSATP on P2X and P2Y receptors.It is possible that the activation of presynaptic P2Y receptors is capable of facilitating neurotransmitter release from preganglionic neurons.On the other hand, incubation with the P2X receptor agonist β,γ-meATP induced an increment rather than an inhibition of acetylcholine release elicited by preganglionic stimulation of canine stellate ganglia.These changes in acetylcholine release induced by the P2X agonist β,γ-meATP and the P2X and P2Y ligand 2MeSATP will require further research.
In sympathetic and parasympathetic ganglia, P2X receptor subtypes are expressed in both presynaptic and postsynaptic compartments; their role in fast transmission is modulatory, largely through the regulation of neurotransmitter release [2].The evidence for the involvement of P2 receptors in the inhibition of acetylcholine release has been obtained in the frog neuromuscular junction [37], rat submandibular ganglia [31], and the rabbit retina [38].ATP activates a presynaptic P2 receptor to inhibit acetylcholine release from preganglionic nerves in the submandibular ganglia.The inhibitory effects of ATP on nerve-evoked transmitter release are antagonized by bath application of PPADS or suramin, suggesting that ATP activates a presynaptic P2 receptor to inhibit acetylcholine release from preganglionic nerves in the submandibular ganglia [31].
However, the specific receptor subtype involved in the α,β-meATP-induced inhibition of sympathetic neurotransmission has not yet been determined.In our experiments, the ATP analog α,β-meATP inhibited sympathetic ganglionic transmission by reducing the acetylcholine release at preganglionic terminals.Furthermore, both the nonspecific P2 receptor antagonist PPADS and the P2X-specific receptor antagonist TNP-ATP, which is a potent antagonist selective for P2X 1 , P2X 3 and heteromeric P2X 2/3 receptors [39], completely antagonized the α,β-meATP-induced inhibition of acetylcholine release elicited by preganglionic stellate stimulation.Taken together, these results indicate that the presynaptic inhibition of acetylcholine output induced by α,β-meATP is mediated by activation of the P2X receptors in the canine presynaptic stellate ganglion.
NOS is widely distributed in the preganglionic sympathetic neurons of rat pre-and paravertebral [23] [40] and superior cervical [24] ganglia.In contrast, NOS is localized to a population of sympathetic postganglionic neurons in the guinea pig paravertebral and inferior mesenteric ganglia [25] and in the cat stellate and lower lumbar ganglia [27].Furthermore, both neuronal NOS (nNOS) and endothelial NOS (eNOS) are naturally present in neuronal tissue [41].
These findings indicate that nNOS is present in pre and/or postganglionic sympathetic neurons.On the other hand, NO plays an important role in the control of synaptic function in both the peripheral and central nervous system [21].In a previous report, we showed that the NO donor S-nitroso-N-acetylpenicillamine reduced the acetylcholine release elicited by preganglionic stellate stimulation in dogs, in a dose-dependent manner [20].ATP acts as a paracrine factor in the thick ascending limb of Henle's loop, inducing NO production via activation of P2X receptors [42].In a recent study, Yukawa et al. [43] showed that extracellular ATP induces NO production in cochlear spiral ganglion neurons, but that this was abolished in the presence of L-NAME.Furthermore, ATP and the P2X agonist α,β-meATP mimicked the effects of ATP to stimulate a rise in [Ca 2+ ] i , leading to nNOS activation and NO production in isolated neurons of the glossopharyngeal nerve; this NO signal was inhibited by the purinergic blocker suramin, the NO inhibitor L-NAME, and the NO scavenger carboxy-PTIO [34].Several studies suggest that P2X receptor activation leads to an increased NO production, proposing a functional link between ATP and NO production [44].In this study on the sympathetic ganglion, the preganglionic inhibition by α,β-meATP of the acetylcholine output elicited by preganglionic stimulation was also inhibited by treatment with 3-bromo-7-nitroindazole, a selective nNOS inhibitor and carboxy-PTIO, a NO scavenger.
On the other hand, exposure to the ATP analog α,β-meATP at a dose of 10 −5 M increased the levels of total NO metabolites in the incubation medium, an increase that disappeared after the addition of TNP-ATP or 3-bromo-7-nitroindazole.In contrast, a high dose of α,β-meATP (10 −4 M), which reduced acetylcholine release, did not significantly increase NO production (Figure 7 and Figure 8).The mechanism of NO production elicited by P2X7 receptor activation may be involved in regulation of neuronal excitability [44].This discrepancy between the inhibition of acetylcholine and NO production at the high dose of α,β-meATP possibly could be involved in the distinction between the presence or absence of electrical stimulation.However, the mechanisms underlying the discrepancy remain to be determined.These results suggest that the increase in NO formation mediated by the activation of P2X receptors may have a role in the α,β-meATP-induced preganglionic inhibition of acetylcholine release in the canine stellate ganglion.
Endogenous NO has been shown in many tissues to affect soluble guanylyl cyclase [45] [46] and to bind tightly to the heme region of this cyclase; it causes an increase in cGMP levels, which affects ion channels [47].ODQ has previously been shown to abolish the elevation of cGMP accumulation induced by nitoprusside in rat superior cervical ganglia [48].In our previous investigation using 8-bromo-cGMP, a membrane-permeable cGMP analog, we found a dose-dependent decrease in acetylcholine release elicited by preganglionic stimulation [20].
In the experiments described here, the inhibition by α,β-meATP of acetylcholine release elicited by preganglionic stellate stimulation was antagonized by treatment with ODQ, a selective inhibitor of soluble guanylyl cyclase.These results suggest that α,β-meATP stimulates the receptor-mediated formation of NO metabolites activating soluble guanylyl cyclase, and thus leads to increased cGMP content in the canine stellate ganglia.

Conclusion
In conclusion, α,β-meATP inhibits sympathetic ganglionic transmission at presynaptic sites via purinergic P2X receptors by reducing the output of acetylcholine release through, at least in part, the stimulation of NO production and cGMP pathways.

2 NO − and 3 NO 2 NO − and 3 NO
− in Locke's solution were subtracted from the sample values in each experiment.The total NO metabolite levels ( NO x − ) were calculated as the sum of the − levels.

Figure 2 .
Figure 2. Effect of the nonselective P2 receptor antagonist, PPADS, on the α,β-methylene-ATP-induced reduction in acetylcholine output elicited by preganglionic stimulation in untreated ( ) and 10 −5 M PPADS-treated ( ) ganglia.In two groups of ganglia, the mean basal amount of acetylcholine released by preganglionic stimulation before drug addition were 5.4 ± 2.06 and 5.8 ± 2.27 nmol/10 min/g.Each column represents mean of 5 ganglia and vertical bars represent SEMs.*significant difference between values before and after α,β-methylene-ATP addition in the same ganglion (p < 0.05).†significant difference between untreated and PPADS-treated ganglia (p < 0.05).Each column represents the mean of 5 ganglia.

Figure 3 .
Figure 3.Effect of the P2X 1 and P2X 3 receptor antagonist, TNP-ATP, on the α,βmethylene-ATP-induced reduction in the acetylcholine output elicited by preganglionic stimulation in untreated ( ) and 10 −7 M TNP-ATP-treated ( ) ganglia.In two groups of ganglia, the mean basal amount of acetylcholine released by preganglionic stimulation before drug addition were 4.6 ± 0.74 and 5.7 ± 1.88 nmol/10 min/g.*significant difference between the values before and after α,β-methylene-ATP addition in the same ganglion (p < 0.05).†significant difference between untreated and TNP-ATP-treated ganglia (p < 0.05).Each column represents the mean of 5 ganglia.See the legends to Figure 2 for additional explanation.

Figure 5 .
Figure 5.Effect of the soluble guanylyl cyclase inhibitor, ODQ, on the α,β-methylene-ATP-induced reduction in acetylcholine output elicited by preganglionic stimulation in untreated ( ) and 10 −5 M ODQ-treated ( ) ganglia.In two groups of ganglia, the mean basal amounts of acetylcholine released by preganglionic stimulation before drug addition were 6.5 ± 0.79 and 6.2 ± 0.62 nmol/10 min/g.*significant difference between the values before and after α,β-methylene-ATP addition in the same ganglion (p < 0.05).†significant difference between untreated and ODQ-treated ganglia (p < 0.05).Each column represents the mean of 5 ganglia.See the legends to Figure2for additional explanation.

Figure 6 .
Figure 6.Effect of the NO scavenger carboxy-PTIO, on the α,β-methylene-ATP-induced reduction in acetylcholine output elicited by preganglionic stimulation in untreated ( ) and 10 −5 M carboxy-PTIO-treated ( ) ganglia.In two groups of ganglia, the mean basal amount of acetylcholine released by preganglionic stimulation before drug addition were 6.7 ± 1.05 and 5.0 ± 0.48 nmol/10 min/g.*significant difference between the values before and after α,β-methylene-ATP in the same ganglion (p < 0.05).†significant difference between untreated and carboxy-PTIO-treated ganglia (p < 0.05).Each column represents the mean of 5 ganglia.See the legends to Figure 2 for additional explanation.